Основні поняття
Personalized treatment for HER2+ breast cancer is achievable through a novel molecular classifier test.
Анотація
The content discusses the development of a new test for HER2+ breast cancer by researchers at Baylor College of Medicine. The test aims to personalize treatment by predicting which patients are suitable for targeted anti-HER treatment or other therapies. Key highlights include:
- Introduction of a multiparameter molecular classifier test for HER2+ breast cancer.
- Importance of personalized treatment based on HER2 protein levels.
- Development of a novel molecular classifier test with three components.
- Validation of the test in clinical trials showing high predictive values.
- Potential for safe treatment de-escalation with personalized therapy.
- Plans for further evaluation in prospective clinical trials.
Статистика
"The findings are reported by Jamunarani Veeraraghavan, MD, and colleagues this week in Clinical Cancer Research."
"HER2+ breast cancer, which represents about 1 of every 5 breast cancers, expresses high levels of HER2 proteins..."
"The team of investigators has been working for years to identify the most effective approach to treat HER2+ breast cancer."
"Test validation in the current study used baseline HER2+ breast cancer tumor specimens obtained from patients who participated in the TBCRC023 and PAMELA clinical trials..."
"A decision-tree algorithm was used to construct GPA cutoffs and classifier of response in TBCRC023, and this yielded a positive predictive value (PPV) of 55% and negative predictive value (NPV) of 94%."
Цитати
"Traditionally, in an effort to eliminate the tumor, we give patients more aggressive treatments, but these also increase the toxicity and affect the patient's quality of life."
"Our findings strongly support that safe treatment de-escalation is possible."
"If validated prospectively, our classifier may function as a molecular triaging tool to safely and appropriately select patients with HER2+ breast cancer for treatment de-escalation."